Myelodysplastic Syndromes
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
Clinical trial comparing ATLG versus ATG for immune reconstitution after allogeneic hematopoietic stem cell transplantation in hematologic m…
-
CLINICAL_TRIALS research · 2025-06-10Clinical Trial Update: Oral-ATO for TP53-mutated Myeloid Malignancies [Phase 2]
A Phase 2 clinical trial evaluating oral arsenic trioxide for TP53-mutated myeloid malignancies, including acute myeloid leukemia and myelod…
-
CLINICAL_TRIALS research · 2025-06-08Clinical Trial Update: Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation [Phase 1]
This Phase 1 trial update discusses orally administered AG-120 (ivosidenib) for IDH1-mutated hematologic malignancies, including relapsed/re…
-
CLINICAL_TRIALS trial_result · 2025-06-05Clinical Trial Update: Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Palifermin (Kepivance) in patients undergoing unrelated donor allogeneic hematopoietic cell transplant…
-
CLINICAL_TRIALS research · 2025-06-04Clinical Trial Update: ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis [Phase 2]
A Phase 2 trial (ABBA CORD) evaluating donor-derived cord blood T cells with abatacept for prophylaxis of acute graft-versus-host disease in…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT [Phase 2]
Phase 2 clinical trial evaluating interferon-α for TP53-mutant myeloid malignancies after allogeneic stem cell transplantation is currently …
-
CLINICAL_TRIALS research · 2025-05-31Clinical Trial Update: Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies [Phase 1]
This is a Phase 1, multi-institutional trial evaluating expanded multi-antigen oriented lymphocytes for very high-risk hematologic malignanc…
-
CLINICAL_TRIALS research · 2025-05-31Clinical Trial Update: Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform
Describes a global Shwachman-Diamond Syndrome patient survey and partnering platform sponsored by the Shwachman-Diamond Syndrome Alliance, I…
-
CLINICAL_TRIALS research · 2025-05-29Clinical Trial Update: Study of 3D189 in Patients With Hematologic Malignancies [Phase 1]
Phase 1 study of 3D189 in hematologic malignancies is active but not recruiting.
-
CLINICAL_TRIALS research · 2025-05-28Clinical Trial Update: Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002) [Phase 1]
An early-phase clinical trial evaluating Tagraxofusp as post-transplant maintenance in patients with CD123-positive acute myeloid leukemia, …
-
CLINICAL_TRIALS research · 2025-05-28Clinical Trial Update: A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) [Phase 1]
Phase 1 study evaluating LYT-200 in adults with relapsed/refractory acute myeloid leukemia or relapsed/refractory high-risk myelodysplastic …
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Phase 1]
Phase 1 study of JNJ-67571244 in relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes has completed.
-
CLINICAL_TRIALS trial_result · 2025-05-22Clinical Trial Update: RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms [Phase 2]
Phase 2 trial update for RVU120 in anemia associated with lower-risk myelodysplastic syndromes. The study status is ACTIVE_NOT_RECRUITING.
-
FDA approval · 2025-05-20FDA Approved: AZACITIDINE — Original Application (Reliance Life Sciences Private Limited)
FDA approved the original application for azacitidine by Reliance Life Sciences Private Limited (ANDA217453), authorizing a generic version …
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS [Phase 2]
Phase 2 trial evaluating BST-236 as a single-agent therapy in adults with relapsed or refractory acute myeloid leukemia or high-risk myelody…
-
CLINICAL_TRIALS research · 2025-05-18Clinical Trial Update: A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML [Phase 1, Phase 2]
Clinical trial update showing CFI-400945 with or without azacitidine is being studied in acute myeloid leukemia, myelodysplastic syndromes, …
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome [Phase 2]
Phase 2 clinical trial update for the IDH2 inhibitor AG-221 (enasidenib) in IDH2-mutated myelodysplastic syndrome; the study is active but n…
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome [Phase 2]
Phase 2 trial of the IDH1 inhibitor ivosidenib (AG-120) in IDH1-mutated myelodysplastic syndromes (also listed for acute myeloid leukemia); …
-
CLINICAL_TRIALS research · 2025-05-18Clinical Trial Update: Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 2, Phase 3]
Phase 2/Phase 3 clinical trial investigating molecular genetics-guided maintenance therapy after allogeneic hematopoietic stem cell transpla…
-
EMA approval · 2025-05-15EMA Authorised: Rytelo (imetelstat) — Geron Netherlands B.V.
EMA authorised Rytelo (imetelstat) for the treatment of anemia in patients with myelodysplastic syndromes. The product has orphan medicine d…
-
CLINICAL_TRIALS trial_result · 2025-05-14Clinical Trial Update: ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients [Phase 2]
Phase 2 trial evaluating ASTX727 with donor lymphocyte infusions after allogeneic stem cell transplantation in very high risk myelodysplasti…
-
CLINICAL_TRIALS research · 2025-05-14Clinical Trial Update: A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept
A clinical trial update assessing treatment patterns and the effectiveness of luspatercept in myelodysplastic syndromes; the study is curren…
-
CLINICAL_TRIALS trial_result · 2025-05-11Clinical Trial Update: Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab [Phase 1]
Phase 1 study evaluating pembrolizumab to augment graft-versus-leukemia effect in patients with myelodysplastic syndromes and acute myeloid …
-
CLINICAL_TRIALS research · 2025-05-06Clinical Trial Update: Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia
A new clinical trial registry entry for patients with myelodysplastic syndromes and acute myeloid leukemia is currently recruiting.
-
CLINICAL_TRIALS research · 2025-05-04Clinical Trial Update: KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children [Phase 2]
This clinical trial update describes a Phase 2 study evaluating KIR-favorable mismatched haploidentical transplantation and KIR polymorphism…